Latest Market News

Ariadne Australia anticipates a net profit of $2.0 million to $3.0 million for FY26, a sharp turnaround from the previous year's loss, driven by strong contributions from Orams Group and gains in key investments despite currency headwinds.

Minbos Resources has secured A$4 million in a discounted placement to fund key milestones at its Cabinda Phosphate Project, including mining commencement and plant construction progress.

Almonty Industries will delist from the Toronto Stock Exchange by July 31, 2026, focusing its trading exclusively on Nasdaq to streamline costs and align with where most activity occurs.

Desert Minerals is kicking off a 1,000-metre RC drilling campaign at its Mt Monger Gold Project, targeting extensions to a 16,400-ounce inferred resource at the Providence Prospect. The project’s strategic location near operating mines and multiple untested targets underpin the company’s growth ambitions.

Pioneer Credit has reported a breakout FY26 with a 248% jump in NPAT to $23.2m and is raising $17m to fuel further Purchased Debt Portfolio investments in FY27.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

Ovanti appoints two early Afterpay executives to its Advisory Board as it prepares to relaunch its BNPL platforms IOUPAY and myIOU, targeting rapid growth in Southeast Asia and beyond.

VHM Limited has secured a binding rare earths offtake and a A$40 million convertible note from Iluka Resources, underpinning the Goschen Project's path to production by late 2027.

Marmota Limited has pushed its Greenewood gold project drilling beyond 20,000 metres in just three months, significantly extending high-grade mineralisation and advancing its maiden scoping study.

HiTech Group Australia is acquiring Hudson Global Resources’ Australian operations for $7 million, significantly broadening its footprint and diversifying services beyond ICT recruitment.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.